Cardiomyocyte p65 Nuclear Factor-κB is necessary for compensatory adaptation to pressure overload

Circulation: Heart Failure

Volumn 8, Issue 1, 2015, Pages 109-118

  Javan, Hadi ^a   Szucsik, Amanda M ^a   Li, Ling ^a   Schaaf, Christin L ^a   Salama, Mohamed E ^b   Selzman, Craig H ^a  

^a Department of Surgery   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Heart decompensation; Hypoxia inducible factor 1; Microcirculation; NF B

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RUNX2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RNA;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; FIBROSIS; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART PRESSURE OVERLOAD; LUNG CONGESTION; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; APOPTOSIS; CARDIAC MUSCLE CELL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 84927725126     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001297     Document Type: Article

References (50)

1. Jones WK, Brown M, Wilhide M, He S, Ren X. NF-kappaB in cardiovascular disease: diverse and specific effects of a "general" transcription factor? Cardiovasc Toxicol. 2005;5:183-202.
2. Valen G. Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure. Basic Res Cardiol. 2004;99:1-7. doi:10.1007/s00395-003-0442-7.
3. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol. 2006;41:580-591. doi:10.1016/j. yjmcc.2006.07.006.
4. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63:487-499. doi:10.1016/j. cardiores.2004.02.013.
5. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-B p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011;89:129-138. doi:10.1093/cvr/cvq274.
6. Ling H, Gray CB, Zambon AC, Grimm M, Gu Y, Dalton N, Purcell NH, Peterson K, Brown JH. Ca2+/Calmodulin-dependent protein kinase II mediates myocardial ischemia/reperfusion injury through nuclear factor-B. Circ Res. 2013;112:935-944. doi:10.1161/ CIRCRESAHA.112.276915.
7. Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;293:H2248-H2253. doi:10.1152/ajpheart.00776.2007.
8. Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg. 2007;84:120-125. doi:10.1016/j.athoracsur.2007.02.049.
9. Tranter M, Ren X, Forde T, Wilhide ME, Chen J, Sartor MA, Medvedovic M, Jones WK. NF-kappaB driven cardioprotective gene programs; Hsp70.3 and cardioprotection after late ischemic preconditioning. J Mol Cell Cardiol. 2010;49:664-672. doi:10.1016/j.yjmcc.2010.07.001.
10. Wilhide ME, Tranter M, Ren X, Chen J, Sartor MA, Medvedovic M, Jones WK. Identification of a NF-B cardioprotective gene program: NF-B regulation of Hsp70.1 contributes to cardioprotection after permanent coronary occlusion. J Mol Cell Cardiol. 2011;51:82-89. doi:10.1016/j. yjmcc.2011.03.011.
11. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-B in the heart: to be or not to NF-B. Circ Res. 2011;108:1122-1132. doi:10.1161/CIRCRESAHA.110.226928.
12. Stansfield WE, Charles PC, Tang RH, Rojas M, Bhati R, Moss NC, Patterson C, Selzman CH. Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile. J Thorac Cardiovasc Surg. 2009;137:232-238, 238e1. doi:10.1016/j. jtcvs.2008.08.019.
13. Stansfield WE, Rojas M, Corn D, Willis M, Patterson C, Smyth SS, Selzman CH. Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res. 2007;142:387-393. doi:10.1016/j.jss.2007.01.037.
14. Zhang X, Javan H, Li L, Szucsik A, Zhang R, Deng Y, Selzman CH. A modified murine model for the study of reverse cardiac remodelling. Exp Clin Cardiol. 2013;18:e115-e117.
15. Andersen NM, Stansfield WE, Tang RH, Rojas M, Patterson C, Selzman CH. Recovery from decompensated heart failure is associated with a distinct, phase-dependent gene expression profile. J Surg Res. 2012;178:72-
16. doi:10.1016/j.jss.2011.12.017.
17. Valen G. Innate immunity and remodelling. Heart Fail Rev. 2011;16:71-
18. doi:10.1007/s10741-010-9187-1.
19. Andersen NM, Tang R, Li L, Javan H, Zhang XQ, Selzman CH. Inhibitory kappa-B kinase-inhibition prevents adaptive left ventricular hypertrophy. J Surg Res. 2012;178:105-109. doi:10.1016/j.jss.2012.03.003.
20. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005;111:2319-2325. doi:10.1161/01.CIR.0000164237.58200.5A.
21. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA. 2001;98:6668-6673. doi:10.1073/pnas.111155798.
22. Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L, Bergmann MW. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res. 2009;84:416-424. doi:10.1093/cvr/cvp237.
23. Kratsios P, Huth M, Temmerman L, Salimova E, Al Banchaabouchi M, Sgoifo A, Manghi M, Suzuki K, Rosenthal N, Mourkioti F. Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKKgamma in cardiomyocytes. Circ Res. 2010;106:133-144. doi:10.1161/CIRCRESAHA.109.202200.
24. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation. 2003;108:664-667. doi:10.1161/01. CIR.0000086978.95976.41.
25. Gupta S, Young D, Maitra RK, Gupta A, Popovic ZB, Yong SL, Mahajan A, Wang Q, Sen S. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol. 2008;375:637-649. doi:10.1016/j. jmb.2007.10.006.
26. Maier HJ, Schips TG, Wietelmann A, Krüger M, Brunner C, Sauter M, Klingel K, Böttger T, Braun T, Wirth T. Cardiomyocyte-specific IB kinase (IKK)/NF-B activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA. 2012;109:11794-11799. doi:10.1073/pnas.1116584109.
27. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013;128:388-400. doi:10.1161/ CIRCULATIONAHA.113.001878.
28. Diwan A, Dorn GW 2nd. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda). 2007;22:56-64. doi:10.1152/physiol.00033.2006.
29. Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY, Whitehead KJ, Salama ME, Selzman CH, Stehlik J, Clayson SE, Bristow MR, Renlund DG, Li DY. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol. 2010;56:382-391. doi:10.1016/j. jacc.2010.04.019.
30. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446:444-448. doi:10.1038/nature05602.
31. Oka T, Akazawa H, Naito AT, Komuro I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ Res. 2014;114:565-571. doi:10.1161/ CIRCRESAHA.114.300507.
32. Zhang XQ, Tang R, Li L, Szucsik A, Javan H, Saegusa N, Spitzer KW, Selzman CH. Cardiomyocyte-specific p65 NF-B deletion protects the injured heart by preservation of calcium handling. Am J Physiol Heart Circ Physiol. 2013;305:H1089-H1097. doi:10.1152/ajpheart.00067.2013.
33. Tang RH, Zheng XL, Callis TE, Stansfield WE, He J, Baldwin AS, Wang DZ, Selzman CH. Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression. Proc Natl Acad Sci USA. 2008;105:3362-3367. doi:10.1073/pnas.0705842105.
34. Dorn GW 2nd. Myocardial angiogenesis: its absence makes the growing heart founder. Cell Metab. 2007;5:326-327. doi:10.1016/j. cmet.2007.04.003.
35. Egginton S, Gaffney E. Tissue capillary supply-it's quality not quantity that counts! Exp Physiol. 2010;95:971-979. doi:10.1113/ expphysiol.2010.053421.
36. Gupta S, Sen S. Role of the NF-kappaB signaling cascade and NFkappaB-targeted genes in failing human hearts. J Mol Med (Berl). 2005;83:993-1004. doi:10.1007/s00109-005-0691-z.
37. Purcell NH, Molkentin JD. Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation. 2003;108:638-640. doi:10.1161/01.CIR.0000085362.40608.DD.
38. Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol. 2008;294:H645-H650. doi:10.1152/ajpheart.00196.2007.
39. Hikoso S, Yamaguchi O, Nakano Y, Takeda T, Omiya S, Mizote I, Taneike M, Oka T, Tamai T, Oyabu J, Uno Y, Matsumura Y, Nishida K, Suzuki K, Kogo M, Hori M, Otsu K. The I{kappa}B kinase {beta}/ nuclear factor {kappa}B signaling pathway protects the heart from hemodynamic stress mediated by the regulation of manganese superoxide dismutase expression. Circ Res. 2009;105:70-79. doi:10.1161/ CIRCRESAHA.108.193318.
40. Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NFB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res. 2012;110:1077-1086. doi:10.1161/ CIRCRESAHA.111.260729.
41. Goldman D. Theoretical models of microvascular oxygen transport to tissue. Microcirculation. 2008;15:795-811. doi:10.1080/10739680801938289.
42. Sidibé A, Imhof BA. VE-cadherin phosphorylation decides: vascular permeability or diapedesis. Nat Immunol. 2014;15:215-217. doi:10.1038/ ni.2825.
43. Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76:39-56. doi:10.1146/ annurev-physiol-021113-170322.
44. Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Görlach A. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 2007;27:755-761. doi:10.1161/01.ATV.0000258979.92828.bc.
45. Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, Kietzmann T, Görlach A. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell. 2007;18:4691-4697. doi:10.1091/mbc.E07-04-0391.
46. Chatterjee A, Mir SA, Dutta D, Mitra A, Pathak K, Sarkar S. Analysis of p53 and NF-B signaling in modulating the cardiomyocyte fate during hypertrophy. J Cell Physiol. 2011;226:2543-2554. doi:10.1002/jcp.22599.
47. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453:807-811. doi:10.1038/nature06905.
48. Frantz S, Hu K, Bayer B, Gerondakis S, Strotmann J, Adamek A, Ertl G, Bauersachs J. Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J. 2006;20:1918-1920. doi:10.1096/ fj.05-5133fje.
49. Timmers L, van Keulen JK, Hoefer IE, Meijs MF, van Middelaar B, den Ouden K, van Echteld CJ, Pasterkamp G, de Kleijn DP. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res. 2009;104:699-706. doi:10.1161/CIRCRESAHA.108.189746.
50. Dhingra R, Gang H, Wang Y, Biala AK, Aviv Y, Margulets V, Tee A, Kirshenbaum LA. Bidirectional regulation of nuclear factor-B and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes. Circ Heart Fail. 2013;6:335-343. doi:10.1161/CIRCHEARTFAILURE.112.000061.